Replies to post #186229 on Anavex Life Sciences Corp (AVXL)

[whippinsaw]

Missling has the most to lose if it goes to zero.
He must know something we dont or he would
Not take the risk. He does not seem like a gambling man.

[falconer66a]

Missling, Like Others, Knows It Won’t Fail

...avoid the possibility of 2-73 failing and his shares being worth zero.

To presume there is a considered chance that Anavex 2-73 simply won’t succeed in any one of the three human trials is to (understandably) reveal an ignorance of vertebrate neuron biochemistry, morphology, physiology, and the molecules and organelles in operation within nerves and neurons; and to fail to understand the unique cellular chemistry of this sigma-1 receptor agonist.

Understood: Not wise to make big bets on new, never-used-in-humans drugs targeting difficult diseases. Few diseases are more difficult than the three central nervous system diseases Anavex is being tested against; in real human beings, not diseased lab rats. Why should Anavex 2-73 work, safely, when so few others have? Why is Dr. Missling both wise and diligent in rejecting buyouts or takeovers of any kind? He’s bet the corporate ranch, has he not, on Anavex 2-73 being successful for either Rett syndrome, Parkinson’s, or Alzheimer’s. Fail with all three, and Anavex Life Sciences Corp is but another historic chapter in some new business administration textbook. MBAs, take heed.

Here are some big things that make Anavex 2-73 different from other new, “unproven” neuroactive drugs. Missling knows all of this, and much more.

1. Profound evidence of both efficacies and safety in murine tests against a multitude of nerve (and other) disorders.

Of course, easy (but in this case, inaccurate) to claim that animal studies simply can’t predict assured efficacies or safety in real human with real diseases. In this case, Missling knows that is NOT the case. (So do I.)

2. The cellular and systemic neurology of mammals, whether in lab rats and mice (murines), or real humans, is virtually identical, regarding the maintenance (homeostasis) of normalized nerve function. This is particularly so in transgenic rats, whose disease states arise from human disease genes inserted into their genomes. Anavex 2-73 fixes those conditions, allowing neurons to restore normal biochemical homeostasis — just as it will in humans (and already has, in a few Australians with already poorly-functioning Alzheimer’s nerves).

3. The testing of the drug in humans has failed to reveal any significant, disqualifying adverse events or outcomes (replicating the safety profiles found in treated murines).

Yes, nerve-acting drugs of every sort are particularly associated with adverse events and outcomes. Nothing of the sort in either murines or humans with Anavex 2-73.

4. Most importantly, Anavex 2-73 works altogether differently from any other drug. Too complicated to detail here, trying to explain the precise interactions of mitochondria, endoplasmic reticula, and protein folding; all controlled or moderated by the sigma-1 receptor complexes (when functioning normally). But Missling and his people know with certainty the profound efficacies and viable safety profiles of their molecules. Simply, they are, in every way, different from other, previous neuroactive drugs. They are safe. And they work.

Interestingly, now, no one with any understanding of neuron biology is posting cautions or statements telling that the mechanisms of action of the Anavex molecules are implausible, unknown, or impossible. Recent external papers describe and affirm the data affirming the health-restoring and health-maintaining validity of them.

The reluctance (even antagonism) of many regarding the possibility of great successes in the three human trials of Anavex 2-73 is understood. No offense taken. A few can accurately read the evidence. Most, however, will decide to wait for significant trial results. Everyone must make decisions on what he or she knows and believes — just as Missling has done.

A year from now, public discourse on matters Anavex will be very different. I’m eager to watch, read, and listen (especially to my brokerage statements).